SEC Form 4 · accession 0001415889-18-000310
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John David Hansen
Officer — PRESIDENT AND CEO · Director
Period of report
Feb 21, 2018
Accepted (ET)
Feb 23, 2018 · 3:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1,F2 | $2.04 | Feb 21, 2018 | A | 290,000 | A | — | Feb 21, 2028 | Common Stock | 290,000 | 290,000 | D |
Explanation of responses
- F1Option award is partial compensation for service as an officer.
- F2The Option Shares shall vest 25% at the 6-month anniversary of the commencement date; with the balance vesting in equal monthly amounts of 4.167% per month over the remaining 18 months until fully vested after 2 years from the commencement date.